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Abstract
We report a case of a 26- year old woman having
antiphospholipid syndrome in pregnancy with long-term
follow up. She presented with recurrent miscarriages,
venous thrombosis, avascular necrosis of femoral head,
mid-cerebral artery infarction and skin ulcers.
Antiphospholipid syndrome is a recognized disorder of
pregnancy. Diagnosis requires a high index of suspicion
when evaluating women with recurrent pregnancy losses
and vascular thrombosis. A low dose aspirin combined with
heparin can reduce morbidity and improves the pregnancy
outcome.
Case Report
A 26-year-old Pakistani primigravida was admitted
in April 1989 at 8 weeks of gestation with a painful right
leg. On examination, the right leg was swollen; calf circum-
ference measured 32cm on the right vs 29.5cm on left and
the over-lying skin was congested. Passive movements of
the calf were painful. A diagnosis of  popliteal vein throm-
bosis was made on Doppler examination and patient was
started on intravenous heparin (1000 units/hour). Complete
blood count showed thrombocytopenia (30X109/L). Further
laboratory investigations revealed antinuclear antibodies
positive1+ whereas, anti-dsDNA, anti-smooth muscle anti-
bodies, anti-mitochondrial antibodies and rheumatoid factor
were negative. Prolonged activated partial thromboplastin
time (APTT) was not correctable with fresh frozen plasma.
The APTT inhibitor test was positive and anti-cardiolipin
IgG was raised to 67GPL/ml. The repeat value 8 weeks later
was 80GPL/ml (normal 9GPL/ml). Repeated antinuclear
antibodies were strongly positive and anti-dsDNA was neg-
ative. The echo cardiogram and chest x-ray were also nor-
mal.
A diagnosis of antiphospholipid syndrome (APS)
was made based on her clinical presentation and laboratory
findings. Low-dose aspirin (75mg daily) was started. She
had a miscarriage at 13 weeks of gestation. Second miscar-
riage occurred at 19 weeks of gestation in 1991. In her third
pregnancy in addition to low-dose aspirin, she received
heparin (5000U subcutaneously daily) and prednisolone
(30mg twice daily). Prednisolone was gradually tapered and
stopped at 24 weeks of gestation. This pregnancy was com-
plicated by severe pre-eclampsia and Caesarean section was
performed at 31 weeks of gestation. The baby died four
months later due to complications of prematurity. She con-
ceived fourth time after infertility treatment in 1995. Low-
dose aspirin and heparin (5000U subcutaneously daily) was
started at 8 weeks of gestation and she was carefully
observed during pregnancy. Platelet counts, blood pressure
and urine for protein were checked at each visit. Fetal sur-
veillance was monitored by kick chart, non-stress test, seri-
al pelvic and Doppler ultrasound examination and biophys-
ical profile. Dexamethasone was given at 30 weeks of ges-
tation to promote fetal lung maturity. A healthy male baby
(weight 3.1kg) was delivered at 37 weeks of gestation by
Caesarean section. The patient was discharged on fifth post-
operative day on low-dose aspirin. She conceived for the
fifth time in 1997, and received treatment as mentioned ear-
lier. A healthy baby boy (weight 2.6kg) was delivered. Due
to the nature of disease, tubal ligation was discussed with
the patient.
In 1999, another episode of popliteal vein thrombo-
sis was initially managed with heparin infusion (30,000U
daily). Later she was switched to warfarin followed by low-
dose aspirin. Her sixth pregnancy in   2001 was complicat-
ed by severe intrauterine growth       restriction (biophysical
profile: 6/10 with suboptimal cardiotocography at 29 weeks
of gestation). Dexamethasone was administered to promote
lung maturity and an elective Caesarean section with tubal
ligation was performed. A baby boy (weight 980 grams) was
delivered and transferred to neonatal intensive care unit.
The patient developed severe hypertension and thrombocy-
topenia on fourth postoperative day for which she received
beta-blockers and corticosteroids. In January 2002, she
developed pain in the left lower limb and skin ulcers. An
MRI revealed avascular necrosis of femoral head. In view
of her progressive symptoms and functional disability, a
total hip arthroplasty was advised. 
In 2003 she developed stroke and MR angiography
showed middle cerebral artery infarction. On a recent fol-
low-up, she was undergoing physiotherapy. Her current
therapy includes warfarin, beta-blocker, low-dose aspirin,
and cholesterol lowering agent.
Discussion
Antiphospholipid syndrome (APS) is characterized
by the presence of antiphospholipid (aPL) antibodies
belonging to a family of immunoglobulins that bind nega-
tively charged phospholipids, phospholipids binding pro-
teins or both. These include lupus anticoagulants (LAC),
anticardiolipin (aCL) antibodies and anti beta 2 glycopro-
tein -1; a co-factor required for the action of LAC and aCL.
Antiphospholipid syndrome is a complex multisystem dis-
order. This syndrome occurs in isolation (primary APS) or
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within context of several autoimmune disorders (secondary
APS).1
Sapporo criteria are considered acceptable for the
diagnosis of APS. These include unexplained or repeated
pregnancy loss around 10 weeks of gestation and positive
aCL IgM and IgG or LAC antibodies on at least 2 occasions
6 weeks apart.2 The reported patient manifests several fea-
tures of APS such as venous thrombosis, repeated pregnan-
cy loss and high titres of aCL and LAC antibodies. 
Prevalence of APS varies according to the popula-
tion assessed, and the Immunoassay used to detect aPL anti-
bodies. The study published by Lockwood et al found a
prevalence of 2.2% for aCL and 0.27% for LAC antibodies
in low risk obstetrics patients.3
The association of positive aPL and LAC antibodies
with recurrent fetal loss is well established and varies
between 4.6 and 50.7% (mean 15.5%) and 0 and 14% (mean
8.3%) respectively.4 The presence of aPL antibodies is also
associated with placenta insufficiency, fetal growth restric-
tion, preeclampsia and preterm delivery.5
In addition to influencing pregnancy outcomes, APS
may affect any organ of the body and display a broad-spec-
trum of manifestations. These include deep venous throm-
bosis (31.7%), thrombocytopenia (21.9%) pulmonary
embolism (9%), transient ischaemic attacks (7%), stroke
(13.1%), myocardial infarction (2.8%), skin ulcers (3.9%)
and rarely a catastrophic syndrome characterized by wide-
spread vascular occlusion (0.8%).6 Most of these systemic
features can be explained by vasculopathy and occlusion of
small vessels due to platelet aggregation and subsequent
thrombosis.
Asymptomatic avascular necrosis (AVS) of femoral
head is seen on MRI in 20% of patients with primary APS.
Though sporadic cases of bilateral or unilateral AVN of
femoral and tibial head has been reported in patients with
primary APS who were not receiving corticosteroids.7,8 Use
of corticosteroids in treatment of APS may aggravate the
risk of avascular necrosis of bones. 
It is difficult to interpret the current literature to
determine the optimal treatment of APS in pregnancy. The
recent trials have focused on comparison of low-dose
aspirin alone with steroids or heparin. In a multicenter ran-
domized trial no difference was found in live birth rates
when low-dose aspirin and heparin was compared with low-
dose aspirin and prednisolone, but patients who received
prednisolone were reported to have increased risk of mater-
nal morbidity and preterm delivery.9 The review of thera-
peutic trials has revealed that the combination of heparin
and aspirin may reduce pregnancy loss by 54%.10
In conclusion, APS is a well-recognized disorder of
pregnancy and is characterized by recurrent miscarriages
and vascular thrombosis. Routine screening of pregnant
women for APS is not recommended as the prevalence is
low. However, anticardiolipin and lupus anticoagulants anti-
bodies must be checked in women presenting for evaluation
of recurrent pregnancy loss. Management of APS is aimed
to improve maternal and fetal outcome. It can be achieved
by preconceptional counseling, referral to specialist and
careful monitoring of pregnancy. Low-dose aspirin com-
bined with heparin may be an appropriate treatment in
women with recurrent pregnancy loss and thrombotic
events.
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